Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 13, 1545-1556

Participation in an Innovative Patient Support Program Reduces Prescription Abandonment for Adalimumab-Treated Patients in a Commercial Population


Participation in an Innovative Patient Support Program Reduces Prescription Abandonment for Adalimumab-Treated Patients in a Commercial Population

Diana Brixner et al. Patient Prefer Adherence.


Purpose: Nonadherence to indicated therapy reduces treatment effectiveness and may increase cost of care. HUMIRA Complete, a Patient Support Program (PSP), aims to reduce nonadherence in patients prescribed adalimumab (ADA). The objective of this study was to assess the relationship between participation in the PSP and prescription abandonment rates among ADA-treated patients.

Patients and methods: This longitudinal study using patient-level data from AbbVie's PSP linked with medical and pharmacy claims data included patients ≥18 years with an ADA-approved indication, ≥1 pharmacy claim for ADA, and available data ≥3 months before and ≥6 months after the index date (defined as the initial ADA claim [01/2015 to 02/2017]). Abandonment was defined as reversal of initial ADA prescription with no paid claim during 3-month follow-up. Abandonment rates were compared between PSP and non-PSP cohorts using multivariable logistic regression controlling for potentially confounding baseline characteristics.

Results: In 17,371 patients (9,851 PSP; 7,520 non-PSP), the overall abandonment rate was 10.8-16.8% across indications. The odds of ADA abandonment were 70% less for PSP vs non-PSP patients (5.6% vs 20.4%, odds ratio [OR]=0.30, [95% confidence interval (CI)=0.27-0.33] P<0.001), 38% less for patients using specialty vs retail pharmacy (OR=0.62, 95% CI=0.56-0.69, P<0.001), 20% less for those with income of $50-99K vs $0-49K (OR=0.80, 95% CI=0.69-0.92, P<0.01), and 78% greater for those with copayment of $26-100 vs $0-25 (OR=1.78, 95% CI=1.55-2.05, P<0.001).

Conclusion: Participation in the PSP, higher income, and using a specialty pharmacy were associated with lower odds of abandoning ADA therapy, whereas increased copayments were associated with greater abandonment. PSPs should be considered to improve initiation of ADA therapy.

Keywords: adherence; drug utilization; managed care; outcomes research/analysis; patient education; personnel management.

Conflict of interest statement

Diana Brixner received consulting fees from AbbVie, AstraZeneca, Becton Dickinson, Millcreek Outcomes Group, Sanofi, and UCB Pharma. Manish Mittal is an employee and stockholder of AbbVie. Dr David T Rubin received consulting fees from AbbVie, Abgenomics, Allergan, Inc., Arena Pharmaceuticals, Biomica, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, Janssen Pharmaceuticals, Lilly, Mahana Therapeutics, Medtronic, Narrow River Mgmt, Pfizer, Prometheus Laboratories, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions, Inc., and investigator-initiated grant support from Takeda. Philip Mease received grant/research support from AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN Pharma, UCB; received consulting fees from AbbVie, Amgen, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, Merck, Novartis, Pfizer, Sun Pharma, and UCB; and was on the speakers bureau for AbbVie, Amgen, BMS, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, and UCB. Matthew Davis is an employee of Medicus Economics, which received payment from AbbVie to participate in this research. Arijit Ganguli is an employee and stockholder of AbbVie. A Mark Fendrick reports personal fees from Merck, AstraZeneca, Trizetto, Johnson & Johnson, Sanofi, AbbVie, Amgen, Centivo, Community Oncology Association, Department of Defense, EmblemHealth, Exact Sciences, Freedman Health, Health at Scale Technologies, Health Management Associates, Lilly, MedZed, PenguinPay, Risalto, Sempre Health, State of Minnesota, Wellth, and Zansors. He also reports grants from AHRQ, Boehringer-Ingelheim, Gary and Mary West Health Policy Center, Laura & John Arnold Foundation, National Pharmaceutical Council, PCORI, PhRMA, RWJ Foundation, and the State of Michigan/CMS. The authors report no other conflicts of interest in this work.


Figure 1
Figure 1
Study sample selection. Notes: aDirect feed claims consisted of filled claims only and were excluded from abandonment analysis. The following treatments were included: etanercept, infliximab, certolizumab, golimumab, anakinra, tocilizumab, secukinumab, ixekizumab, ustekinumab, abatacept, rituximab, natalizumab, vedolizumab, tofacitinib, and apremilast. bClaims with government-provided insurance were excluded as these patients were prohibited from using all components of the PSP. cDetermined using all available claims from 1/1/2006 to the index date. dAutoimmune diseases included rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, and uveitis. Abbreviations: ADA, adalimumab; AS, ankylosing spondylitis; HS, hidradenitis suppurativa; IBD, inflammatory bowel disease; PsA, psoriatic arthritis; PsO, psoriasis; PSP, patient support program; RA, rheumatoid arthritis; UV, uveitis.
Figure 2
Figure 2
Prevalence of abandonment by PSP participation for the overall study population and individual indications. Notes: Relative percent change = (PSP–Non-PSP)/Non-PSP. Asterisk (*) indicates the comparison of PSP versus non-PSP cohorts was statistically significant (P<0.001). P-value was based on 2-sample z-test of proportions. Abbreviations: AS, ankylosing spondylitis; HS, hidradenitis suppurativa; IBD, inflammatory bowel disease; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; UV, uveitis.

Similar articles

See all similar articles


    1. Institute of Medicine. Value in Health Care: Accounting for Cost, Quality, Safety, Outcomes, and Innovation: Workshop Summary. Washington, DC: The National Academies Press; 2010.
    1. Deodhar A, Mittal M, Reilly P, et al. Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. Clin Rheumatol. 2016;35(7):1769–1776. doi:10.1007/s10067-016-3231-z - DOI - PMC - PubMed
    1. Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis. 2010;69(1):222–225. doi:10.1136/ard.2008.102509 - DOI - PubMed
    1. Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109(11):1771–1780. doi:10.1038/ajg.2014.242 - DOI - PMC - PubMed
    1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. doi:10.1056/NEJMoa050516 - DOI - PubMed